J&J’s Duato Makes 358 Times His Median Employee; Vertex CEO Makes Just 80 Times

Why It Matters

The stark disparity highlights growing scrutiny of executive pay equity in a sector where talent retention and public perception are increasingly tied to compensation fairness. Investors and regulators may pressure firms to narrow gaps or improve disclosure.

Key Takeaways

• Duato's $32.6M pay equals 358:1 ratio vs median J&J worker.
• Vertex CEO's ratio 80:1 is lowest among top pharma CEOs.
• Median J&J employee salary $91k, lowest among ten firms studied.
• Pharma CEO pay far exceeds average U.S. employee wage of $69.8k.

Pulse Analysis

The latest BioSpace analysis underscores a widening chasm between pharmaceutical CEOs and their rank‑and‑file workers. Johnson & Johnson’s Joaquin Duato topped the list with a 358‑to‑1 pay ratio, a jump from 293‑to‑1 the year before, while Eli Lilly’s David Ricks and Pfizer’s Albert Bourla trailed but still maintained ratios above 250‑to‑1. By contrast, Vertex Pharmaceuticals set a modest benchmark; Reshma Kewalramani’s $21.2 million compensation paired with a median employee salary of $264,487, yielding the lowest 80‑to‑1 ratio among the sector’s leaders. These figures illustrate how CEO pay packages, often bolstered by stock awards and bonuses, have outpaced median employee earnings, especially at firms where staff wages sit near the lower end of the industry spectrum.

Beyond headline numbers, the pay gap carries tangible business implications. A pronounced disparity can erode morale, hinder talent acquisition, and fuel activist shareholder campaigns demanding greater pay transparency and alignment with ESG goals. Companies like J&J, which reported the lowest median employee salary among its peers, may face heightened scrutiny from labor groups and regulators seeking to ensure equitable compensation practices. Moreover, the gap feeds into broader debates about income inequality in the United States, where the average worker earned just $69,846 in 2024, far below the compensation levels of pharma executives.

The trend mirrors a broader corporate pattern: CEO pay across all industries rose 23 % in 2025, with the average reaching $29.4 million, according to Equilar. While some argue that high compensation reflects the responsibility of steering multi‑billion‑dollar enterprises, investors are increasingly weighing pay ratios as a proxy for governance quality. Firms may respond by tightening compensation committees, linking bonuses more closely to employee‑wide performance metrics, or publicly disclosing pay ratios to mitigate reputational risk. As the conversation around pay equity gains momentum, pharma CEOs will likely confront growing pressure to justify their remuneration relative to the workforce that drives drug development and patient care.